Curis | CRIS - Ebit


Curis reported $-11.52M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Alaunos Therapeutics USD -952K 60K Jun/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bayer EUR 129M 626M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
CSL USD 2.64B 116M Dec/2025
Curis USD -11.52M 3.64M Mar/2026
Eli Lilly USD 13.09B 635M Sep/2026
Exelixis USD 268.42M 20.01M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Verastem USD -44.9M 3.42M Mar/2026